Space Force general says US can now build 'space-based' missile defense system
Space Force
general says the United States now possesses the technological capability to develop a space-based
missile defense system
, calling the long-envisioned concept "ready to be realized."
General Michael Guetlein
, Vice Chief of
Space Operations
and newly appointed head of the
Golden Dome
program, declared this week that every core element required to build and deploy
space-based interceptors
already exists. Speaking at the Innovate Space: Global Economic Summit on July 22, hosted at
Amazon
's corporate headquarters, Guetlein said the US has reached a turning point.
Explore courses from Top Institutes in
Please select course:
Select a Course Category
Technology
Product Management
PGDM
others
Management
Data Science
MBA
Artificial Intelligence
Design Thinking
Data Science
CXO
Healthcare
Cybersecurity
Public Policy
Data Analytics
Operations Management
Others
MCA
Digital Marketing
Finance
Project Management
Degree
Leadership
healthcare
Skills you'll gain:
Duration:
12 Weeks
MIT xPRO
CERT-MIT XPRO Building AI Prod India
Starts on
undefined
Get Details
'I firmly believe that the technology we need to deliver Golden Dome exists today,' Guetlein told attendees. 'It has just never been brought to bear on this problem set to protect the homeland, nor has it been brought to bear in this form factor.'
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
6 Ways Retirees Can Potentially Minimize RMD Taxes
SmartAsset
Learn More
Undo
A modern answer to an old vision
Golden Dome is the Trump administration's flagship missile defense initiative aimed at intercepting hypersonic, cruise, and ballistic missiles from space. Though such a system has never been deployed, the idea has historical roots: President Ronald Reagan's 1983 Strategic Defense Initiative (SDI) proposed similar space-based defenses, which were criticized at the time as technologically unfeasible.
Live Events
Four decades later, Guetlein insists the difference is clear: the science is no longer speculative.
Technological readiness vs organizational challenges
While Guetlein expressed confidence in the technological readiness of Golden Dome, he also acknowledged that building the system will require a major cultural and structural shift within the US defense community.
'How do I take capabilities that were built in stovepipes for different mission areas, amongst different services and agencies, and bring those together into an integrated architecture?' he asked.
He pointed to long-standing silos between military branches and defense contractors that have hindered coordination, saying that resolving these barriers is now a key priority.
Guetlein drew from his experience in the Air Force to explain the shift. 'Historically, there was a reluctance to share sensitive information with commercial industry. But now, with the Space Force increasingly turning to private partners for cutting-edge capabilities, that mindset is changing.'
'Space is too big for the Space Force to go it alone,' he said.
A broader shift in military strategy
Guetlein's remarks align with recent statements by other Space Force leaders. General Chance Saltzman, Chief of Space Operations, told the annual Space Symposium in Colorado Springs that leveraging innovation from the private sector would be critical to US security in space.
'We must harness the benefits of technological innovation and emerging capabilities if we're going to out-compete our competitors,' Saltzman said. 'Historically, military success has hinged on support from commercial industry.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
20 minutes ago
- Time of India
'Game-changing': Piyush Goyal lauds India-UK FTA; calls it 'stepping stone towards dream of Viksit Bharat'
NEW DELHI: Union commerce and industry minister Piyush Goyal on Saturday hailed the newly signed free trade agreement with the United Kingdom and said that the deal was signed on India's terms. While addressing a press conference, Goyal claimed the FTA to be "important" and "game-changing," stating that 99 per cent of India's exports will be able to go to the UK duty-free. "Prime Minister Narendra Modi and UK Prime Minister Keir Starmer signed a Free Trade Agreement. Cabinet approval has been given in India, but Parliamentary approval in the UK is pending," Goyal said. "It will be a game-changing FTA that will give immense opportunities and benefits to India's farmers, businessmen, MSME sector, youngsters, and fishermen. Out of all FTAs signed so far, the India-UK FTA has been the biggest, most comprehensive, and most important. This FTA has been signed on our terms. Ninety-nine per cent of our exports will be able to go to the UK duty-free,' he added. — ANI (@ANI) This comes after India and the UK signed a historic trade deal in the presence of Prime Minister Narendra Modi and UK PM Starmer. The deal was finalised during PM Modi's visit to the United Kingdom. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Salma Hayek, 58,Shows Her Huge Size In New Photos Boite A Scoop Undo The agreement aims to boost bilateral trade to $120 billion by 2030—effectively doubling the current trade volume between the two nations. Taking a swipe at the previous UPA government, Goyal criticised its trade strategy while highlighting the Modi government's approach to FTAs. He also said that the comprehensive deal will help advance progress towards a Viksit Bharat. Goyal said, "UPA government signed FTAs with our competitors, with those countries who would sell their products in India for cheaper prices to destroy India's manufacturing sector... The FTAs signed during the UPA rule were not in the best interests of the country. FTAs signed by PM Narendra Modi are with Mauritius, Australia, EFTA countries, UAE, and now the UK." "Talks are going on with other developed countries. India now signs FTAs with countries which do not compete with us, but complement us. The UK-India Comprehensive Economic and Trade Agreement will prove to be a stepping stone towards our dream of a Viksit Bharat," he added. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Time of India
41 minutes ago
- Time of India
Italy's Meloni: Recognising Palestinian state before it is established may be 'counterproductive'
Italy's Prime Minister Giorgia Meloni said on Saturday that recognising the State of Palestine before it is established could be counterproductive. "I am very much in favour of the State of Palestine but I am not in favour of recognising it prior to establishing it," Meloni told Italian daily La Repubblica. Explore courses from Top Institutes in Please select course: Select a Course Category Digital Marketing Project Management MCA Design Thinking Technology Degree PGDM Management Data Analytics healthcare Artificial Intelligence Cybersecurity Others Product Management MBA others Data Science Public Policy Leadership Healthcare Data Science Operations Management CXO Finance Skills you'll gain: Digital Marketing Strategies Customer Journey Mapping Paid Advertising Campaign Management Emerging Technologies in Digital Marketing Duration: 12 Weeks Indian School of Business Digital Marketing and Analytics Starts on May 14, 2024 Get Details Skills you'll gain: Digital Marketing Strategy Search Engine Optimization (SEO) & Content Marketing Social Media Marketing & Advertising Data Analytics & Measurement Duration: 24 Weeks Indian School of Business Professional Certificate Programme in Digital Marketing Starts on Jun 26, 2024 Get Details "If something that doesn't exist is recognised on paper, the problem could appear to be solved when it isn't," Meloni added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play War Thunder now for free War Thunder Play Now Undo France's decision to recognise a Palestinian state at the United Nations General Assembly in September drew condemnation from Israel and the United States, amid the war in Gaza between Israel and Palestinian militant group Hamas. On Friday, Italy's foreign minister said recognition of a Palestinian state must occur simultaneously with recognition of Israel by the new Palestinian entity. Live Events A German government spokesperson said on Friday that Berlin was not planning to recognise a Palestinian state in the short term and said its priority now is to make "long-overdue progress" towards a two-state solution .
Time of India
44 minutes ago
- Time of India
So it was not diabetes but the common diabetes pill which was causing heart disease! Shocking research reveals the unbelievable!
For many living with type 2 diabetes, managing blood sugar is a daily reality. Often, medications come as a lifeline, and among them, sulfonylureas like glipizide are popular choices, especially in the US. They've been around for decades, are affordable, and have shown effective results in keeping glucose in check. But now, a new study has cast a shadow over this commonly used medicine. Researchers have discovered a possible link between glipizide and increased heart-related risks. Here's what the study found, what it truly means, and why this matters to families where diabetes is part of everyday conversations. Glipizide: Familiar, trusted, But now under scrutiny Glipizide belongs to a group of drugs called sulfonylureas. For decades, these medications have been trusted for lowering blood sugar in people with type 2 diabetes, often when metformin alone isn't enough. What made glipizide popular was its affordability and long-standing availability. But popularity doesn't always mean perfection. The latest study signals a possible red flag. Involving nearly 48,000 individuals, this research found that those taking glipizide had a higher risk of heart attacks, strokes, heart failure hospitalisations, and even cardiovascular-related deaths than those taking a newer class of drugs called DPP-4 inhibitors. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like You Won't Believe the Price of These Dubai Apartments Binghatti Developers FZE Get Offer Undo The numbers that raised eyebrows The research compared glipizide with other sulfonylureas like glimepiride and glyburide, along with DPP-4 inhibitors. Here's what stood out: Over a 5-year period, the risk of major heart events was 9.1% in those taking glipizide, while for those on DPP-4 inhibitors, it was 8.1%. The risk ratio for glipizide users was 1.13, indicating a 13% higher risk of cardiovascular events compared to DPP-4 inhibitor users. The risk was also slightly higher with glimepiride (8.6%) and glyburide (8.4%), but not statistically significant. What makes this important is that most participants were on their second diabetes medication after metformin, a common scenario in diabetes care. And they weren't at extremely high cardiac risk to begin with, just moderate, everyday individuals managing a chronic condition. Not just about the numbers, but about what they mean It's easy to be alarmed by statistics. But what do these numbers truly tell us? Firstly, the study doesn't claim that glipizide causes heart problems directly. What it suggests is a possible association, a pattern that raises concerns, especially in people already facing moderate cardiovascular risk. The heart, after all, is already under pressure in type 2 diabetes. When a drug meant to help with sugar control potentially adds to that risk, even slightly, it becomes a serious discussion for healthcare providers. Why affordability might come at a cost Sulfonylureas like glipizide are often the go-to option in low- and middle-income settings because they're inexpensive. DPP-4 inhibitors, on the other hand, are costlier but have a more favourable cardiovascular safety profile. This raises a deeper, more sensitive question: should treatment decisions depend on cost or safety? The answer isn't straightforward. But studies like this push for better informed decisions, where doctors weigh more than just sugar levels, they also look at heart health, overall risk, and long-term quality of life. What this means for families dealing with diabetes This isn't about pushing panic buttons. Glipizide is still an approved and effective drug. But the study offers important insights for personalised diabetes management. It's a reminder that medications work differently for different people, and what works well for one might not be ideal for another, especially when silent risks like cardiovascular strain are involved. It's also a cue to revisit older medications with a fresh lens, especially when newer, safer options are available. The story here isn't about fear, but about awareness and agency. (Inputs from agencies)
